🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 3 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/05/2024 15,27 16,38 15,13 15,50 +1,77% 8,19% 613.000
30/04/2024 15,38 15,69 15,14 15,23 -2,56% 3,58% 553.400
29/04/2024 15,32 15,93 15,20 15,63 +0,51% 4,77% 624.400
26/04/2024 14,73 15,62 14,59 15,55 +5,57% 6,96% 505.400
25/04/2024 15,19 15,19 14,65 14,73 -4,54% 3,55% 475.000
24/04/2024 15,49 15,85 14,71 15,43 -0,45% 7,36% 524.100
23/04/2024 14,77 15,62 14,57 15,50 +5,59% 7,11% 582.500
22/04/2024 14,67 15,19 14,51 14,68 +0,62% 4,64% 451.000
19/04/2024 14,77 15,19 14,10 14,59 -1,68% 7,38% 597.300
18/04/2024 14,74 14,94 14,51 14,84 +0,00% 2,92% 914.000
17/04/2024 15,95 16,04 14,79 14,84 -6,49% 7,84% 791.400
16/04/2024 16,32 16,62 15,85 15,87 -2,58% 4,72% 329.000
15/04/2024 16,56 16,66 16,03 16,29 -1,75% 3,80% 433.300
12/04/2024 17,21 17,50 16,17 16,58 -4,11% 7,75% 492.200
11/04/2024 16,92 17,37 16,66 17,29 +3,35% 4,20% 378.300
10/04/2024 16,91 17,12 16,50 16,73 -4,13% 3,66% 507.700
09/04/2024 17,04 17,64 16,83 17,45 +2,83% 4,75% 495.300
08/04/2024 17,41 17,56 16,69 16,97 -2,13% 5,00% 285.900
05/04/2024 17,08 17,35 16,61 17,34 +0,41% 4,33% 496.900
04/04/2024 17,80 18,06 17,21 17,27 -2,37% 4,78% 580.100
03/04/2024 17,62 17,84 17,00 17,69 -0,17% 4,77% 564.800
02/04/2024 18,03 18,27 17,57 17,72 -4,11% 3,85% 891.400
01/04/2024 18,78 18,85 18,22 18,48 -2,12% 3,35% 514.800
28/03/2024 18,30 19,11 18,18 18,88 +3,68% 5,08% 744.400
27/03/2024 16,90 18,54 16,64 18,21 +9,37% 11,23% 1.005.700
26/03/2024 16,66 16,75 16,31 16,65 +1,09% 2,61% 917.300
25/03/2024 16,47 16,69 16,10 16,47 +0,24% 3,58% 578.400
22/03/2024 17,15 17,22 16,37 16,43 -4,70% 4,96% 574.800
21/03/2024 17,48 18,08 17,22 17,24 -1,43% 4,92% 620.100
20/03/2024 17,19 17,67 17,01 17,49 +1,10% 3,83% 485.700